Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 5/20 | 0.41 |
| ▸ | AVPR1A | P37288 | 3/20 | 0.41 |
| ▸ | MMP1 | P03956 | 8/20 | 0.40 |
| ▸ | MMP3 | P08254 | 7/20 | 0.40 |
| ▸ | MMP7 | P09237 | 7/20 | 0.40 |
| ▸ | MMP13 | P45452 | 3/20 | 0.37 |
| ▸ | MMP2 | P08253 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | ACE | P12821 | 2/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31743283 | 1.00 | OXTR (0.41) | OXTRAVPR1AMMP1MMP3MMP7 | |
| SCHEMBL4422935 | 1.00 | OXTR (0.41) | OXTRAVPR1AMMP1MMP3MMP7 | |
| SCHEMBL6873980 | 0.89 | OXTR (0.39) | OXTRAVPR1AMMP1MMP3MMP7 | |
| SCHEMBL5946276 | 0.89 | OXTR (0.39) | OXTRAVPR1AMMP1MMP3MMP7 | |
| SCHEMBL27621658 | 0.89 | OXTR (0.39) | OXTRAVPR1AMMP1MMP3MMP7 | |
| SCHEMBL5946274 | 0.89 | OXTR (0.39) | OXTRAVPR1AMMP1MMP3MMP7 | |
| SCHEMBL5946182 | 0.85 | OXTR (0.43) | OXTRAVPR1AMMP1MMP3MMP7 | |
| SCHEMBL5946177 | 0.85 | OXTR (0.43) | OXTRAVPR1AMMP1MMP3MMP7 | |
| SCHEMBL5946005 | 0.83 | HSD17B10 (0.39) | OXTRAVPR1AMMP1MMP3MMP7 | |
| SCHEMBL4945424 | 0.83 | HSD17B10 (0.39) | OXTRAVPR1AMMP1MMP3MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1444225-B1 | PYRROLIDINE OXADIAZOLE- AND THIADIAZOLE OXIME DERIVATIVES BEING OXYTOCIN RECEPTOR ANTAGONISTS. | MERCK SERONO SA (CH) | 2012-10-10 | — | — | EP | disclosed |
| EP-1532109-B1 | PYRROLIDINE DERIVATIVES AS OXYTOCIN ANTAGONISTS | MERCK SERONO SA (CH) | 2009-09-09 | — | — | EP | disclosed |
| EP-1390347-B1 | PYRROLIDINE ESTER DERIVATIVES WITH OXYTOCIN MODULATING ACTIVITY | SERONO LAB (CH) | 2008-05-07 | — | — | EP | disclosed |
| EP-1829861-A2 | Pyrrolidine ester derivatives active as oxytocin antagonists | Applied Research Systems ARS Holding N.V. (AN) | 2007-09-05 | — | — | EP | disclosed |
| US-20070129381-A1 | PHARMACEUTICALLY ACTIVE PYRROLIDINE ESTER DERIVATIVES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-06-07 | — | — | US | disclosed |
| US-7189754-B2 | Pyrrolidine ester derivatives with oxytocin modulating activity | APPLIED RESEARCH SYSTEMS ARS HOLDING NV (AN) | 2007-03-13 | — | — | US | disclosed |
| US-20060229343-A1 | Pyrrolidine oxadiazole-and thiadiazole oxime derivatives being oxytocin receptor antagonists | APPLIED RESEARCH SYSTEMS ARS HOLDDING N.V. (NL) | 2006-10-12 | — | — | US | disclosed |
| US-7115754-B2 | Pyrrolidine derivatives as oxytocin antagonists | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2006-10-03 | — | — | US | disclosed |
| US-7115639-B2 | Pyrrolidine oxadiazole- and thiadiazole oxime derivatives being oxytocin receptor antagonists | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2006-10-03 | — | — | US | disclosed |
| US-20060004020-A1 | Pyrrolidine derivatives as oxytocin antagonists | MERCK SERONO SA (CH) | 2006-01-05 | — | — | US | disclosed |
| EP-1532109-A1 | PYRROLIDINE DERIVATIVES AS OXYTOCIN ANTAGONISTS | Applied Research Systems ARS Holding N.V. (AN) | 2005-05-25 | — | — | EP | disclosed |
| US-20040220238-A1 | Pyrrolidine oxadiazole-and thiadiazole derivatives | MERCK SERONO SA (CH) | 2004-11-04 | — | — | US | disclosed |
| US-20040147511-A1 | Pyrrolidine ester derivatives with oxytocin modulating activity | MERCK SERONO SA (CH) | 2004-07-29 | — | — | US | disclosed |
| EP-1390347-A1 | PYRROLIDINE ESTER DERIVATIVES WITH OXYTOCIN MODULATING ACTIVITY | Applied Research Systems ARS Holding N.V. (AN) | 2004-02-25 | — | — | EP | disclosed |
| WO-2004005249-A1 | PYRROLIDINE DERIVATIVES AS OXYTOCIN ANTAGONISTS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2004-01-15 | — | — | WO | disclosed |
| WO-2002074741-A1 | PYRROLIDINE ESTER DERIVATIVES WITH OXYTOCIN MODULATING ACITVITY | APPLIED RESEARCH SYSTEMS ARS HOLDING NV (AN) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220238-A1 | Pyrrolidine oxadiazole-and thiadiazole derivatives | OXTR, PRLHR, PGF | OXTR 1/4885AVPR1A 16/4885MMP1 3569/4885 |
| US-20060229343-A1 | Pyrrolidine oxadiazole-and thiadiazole oxime derivatives being oxytocin receptor antagonists | OXTR, PRLHR, OXER1 | OXTR 1/4885AVPR1A 18/4885MMP1 4151/4885 |
| US-20060004020-A1 | Pyrrolidine derivatives as oxytocin antagonists | OXTR, PRLHR, AVPR1A | OXTR 1/4885AVPR1A 3/4885MMP1 3593/4885 |
| US-20070129381-A1 | PHARMACEUTICALLY ACTIVE PYRROLIDINE ESTER DERIVATIVES | OXTR, GPR6, CNR1 | OXTR 1/4885AVPR1A 39/4885MMP1 4211/4885 |
| US-20040147511-A1 | Pyrrolidine ester derivatives with oxytocin modulating activity | OXTR, OPRL1, OPRD1 | OXTR 1/4885AVPR1A 28/4885MMP1 4346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.